WT1 and ovarian cancer: Thus, in breast cancer, higher ELF3 or lower WT1 levels associated with worse outcomes, while in colorectal and ovarian cancer, lower ELF3 or higher WT1 levels had worse prognosis, reminiscent of the antagonistic role of ELF3 and WT1 in mediating phenotypic plasticity.